The accelerated progression dynamics of trisomy 12 positive M-CLL was not observed in ibrutinib-treated CLL patients, which implies that inhibition of trisomy 12 mediated BcR activation compensated for this disadvantage. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.